Navigation Links
Grafting of human spinal stem cells into ALS rats best with immunosuppressant combination
Date:12/19/2011

Tampa, Fla. (Dec, 19 2011) A team of researchers grafting human spinal stem cells into rats modeled with amyotrophic lateral sclerosis (ALS), also known as "Lou Gehrig's Disease," a degenerative, lethal, neuromuscular disease, have tested four different immunosuppressive protocols aimed at determining which regimen improved long-term therapeutic effects. Their study demonstrated that a combined, systematically delivered immunosuppression regimen of two drugs significantly improved the survival of the human spinal stem cells. Their results are published in the current issue of Cell Transplantation (20:8), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/.

"There are no therapeutic strategies that successfully modify ALS progression or outcome," said study corresponding author Dr. Michael P. Hefferan of the University of California-San Diego Neurodegeneration Laboratory. "Cell-based transplantation therapies have emerged as potential treatments for several neurological disorders, including ALS. However, cell graft survival seems to greatly depend on an accompanying immunosuppression regimen, yet there are differential responses to identical immunosuppressive therapies."

While the reason for this differential response is unclear, the study authors suggest that several mechanisms, including distinct types of acute and inflammatory responses, may be to blame.

Their study aimed at optimizing an immunosuppressive protocol for transplanting human spinal cord cells into presymptomatic ALS G93A rats with the G93A superoxide dismutase (SOD1) mutation. Two drugs, tacrolimus (FK506) and mycophenolate, were used alone and in combination.

"Although FK506 has been used successfully as monotherapy in our previous studies of spinal ischemia, it failed in the present study on ALS," explained Dr. Hefferan, who speculated that inflammation played a role in the failure. "In contrast to ALS, where spinal inflammation continues and likely worsens until endstage, the traumatically-injured spinal cord is typically characterized by an acute inflammatory phase followed by a progressive loss of most inflammatory markers."

According to the researchers, the animals receiving combined immunosuppression of both FK506 and mycophenolate likely benefited from the longer half-life of mycophenolate rather than from its action.

"The addition of mycophenolate seemed to supplement inhibition of T-cell formation and led to a robust graft survival when analyzed three weeks after grafting," concluded Dr. Hefferan.


'/>"/>

Contact: David Eve
celltransplantation@gmail.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Is root grafting a positive, cooperative behavior in trees?
2. April grafting optimal for Fraser fir
3. Nitrogen from humans pollutes remote lakes for more than a century
4. Remote wilderness polluted by humans
5. 10 years after attacks on World Trade Center, human health cost is still being counted
6. Swarms of bees could unlock secrets to human brains
7. Decision making in bee swarms mimic neurons in human brains
8. Human, artificial intelligence join forces to pinpoint fossil locations
9. Predictive health symposium will focus on human microbiome
10. Finnish researchers discover regulator of human cell activity
11. Creation of the largest human-designed protein boosts protein engineering efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
(Date:2/14/2017)... WINSTON-SALEM, N.C. , Feb. 14, 2017  Wake ... FRY-shlog), M.D., as its new chief executive officer (CEO). ... succeeds CEO John D. McConnell , M.D., who ... new position at the Medical Center, after leading it ... oversee the full scope of Wake Forest Baptist,s academic ...
(Date:2/9/2017)... , Feb. 9, 2017 The biomass ... analysis of the biomass boiler market globally in terms ... of biomass boilers. The market for biomass boilers has ... type, end-user, application, and country/region. The market based on ... & forest residues, biogas & energy crops, urban residues, ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... The Global Market for Bioproducts Should Reach $714.6 Billion by ... 8.9%, This research report quantifies the two ... segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite materials, ...
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... 23, 2017 According to a report by ... market is fragmented due to the presence of a large pool of ... Thermo Fisher , and Sigma-Aldrich, compete with each other in this ... held more than 76% of this market in 2016.  ... As of now, a large ...
(Date:3/22/2017)... N.Y. , March 22, 2017 Regeneron Pharmaceuticals, ... the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to ... the U.K. Biobank resource. The initiative will enable researchers to ... new medicines for a wide range of serious and life ... ...
Breaking Biology Technology: